-

NeuPath Health to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

TORONTO--(BUSINESS WIRE)--NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced that Joseph Walewicz, CEO, will be presenting at the 2023 Bloom Burton & Co. Healthcare Investor Conference.

Date: Wednesday, April 26, 2023
Time: 4:00 p.m. ET
Format: 30-minute live virtual presentation, including Q&A

To register for the presentation, please visit the Investors section of our website at: https://www.neupath.com/investors/decks-presentations. A replay of the webcast will remain available for 90 days following the presentation.

About the Conference

The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings.

About NeuPath

NeuPath operates a network of healthcare clinics and related businesses focused on improved access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centered multidisciplinary care. We operate a network of medical clinics in Ontario and Alberta that provide comprehensive assessments and rehabilitation services to clients with chronic pain, musculoskeletal/back injuries, sports related injuries and concussions. In addition, NeuPath provides workplace health services and independent medical assessments to employers and disability insurers through a national network of healthcare providers, as well as contract research services to pharmaceutical and biotechnology companies. NeuPath is focused on enabling each individual we treat to live their best life.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS THE RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Contacts

Jeff Zygouras
Chief Financial Officer
info@neupath.com
(905) 858-1368

NeuPath Health Inc.

TSX VENTURE:NPTH

Release Versions

Contacts

Jeff Zygouras
Chief Financial Officer
info@neupath.com
(905) 858-1368

More News From NeuPath Health Inc.

NEUPATH HEALTH ANNOUNCES VOTING RESULTS FROM THE ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS

TORONTO--(BUSINESS WIRE)--NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced the voting results from its Annual General and Special Meeting of Shareholders (the “Meeting”) held on June 11, 2025 and the grant of stock options (“Options”) and restricted share units (“RSUs”). All figures are in Canadian dollars, unless otherwise noted. The results of the director elections wer...

NEUPATH HEALTH REPORTS FIRST QUARTER 2025 RESULTS

TORONTO--(BUSINESS WIRE)--NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced its financial and operating results for the three months March 31, 2025 and the grant of stock options (“Options”) and restricted share units (“RSUs”). All figures are in Canadian dollars, unless otherwise noted. “Strong organic growth in Alberta and Ontario, combined with careful attention to our...

NEUPATH HEALTH TO REPORT Q1 RESULTS AND HOST INVESTOR WEBINAR

TORONTO--(BUSINESS WIRE)--NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced that it will release its financial results for the first quarter of 2025 before market open on Thursday, May 15, 2025. Investors and stakeholders are invited to join a live webinar with Joe Walewicz, Chief Executive Officer of NeuPath, for a detailed presentation and discussion of the Company’s res...
Back to Newsroom